ClinicalTrials.gg
CompletedNCT06723535Updated Oct 14, 2025

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

A Phase 1 interventional study of BMS-986278 in Kidney Failure, Chronic, Healthy Volunteers and Renal Impairment, sponsored by Bristol-Myers Squibb. Completed at 4 sites in United States. Open to participants aged 18 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
408th of 638
27 · median 48
Started
2024
with 23 others
Phase 1
89 of 765
8 open now
Registered
733rd of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 408th largest by enrollment of the 638 interventional ones that give a count, is one of 24 that started in 2024, is one of 89 in phase 1, and was the 733rd registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of severe renal impairment (RI) and end-stage renal disease (ESRD) with intermittent hemodialysis (IHD) on the pharmacokinetics and safety of BMS-986278. This study plans to use a staged design based on RI severity.

03

Conditions studied

  • Kidney Failure, Chronic
  • Healthy Volunteers
  • Renal Impairment
04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18 and 45 kg/m2 inclusive, and body weight ≥ 50 kg at screening. Note: for ESRD participants, this body weight should be the prescription dry weight.
  • Severe Renal Impaired Participants:

    1. Participant has a supine SBP ≥ 90 and ≤ 180 mmHg, supine DBP ≥ 60 and ≤ 100 mmHg, and heart rate ≥ 40 and ≤ 110 beats per minute.
    2. Participant has severe RI as defined by an ˂ 30 mL/min and not requiring dialysis at screening.
    3. Participant must be medically stable for at least 1 month before study intervention administration.
  • Participants with ESRD:

    1. Participant has ESRD as defined by an eGFR \< 15 mL/min at screening.
    2. Participant required to be on intermittent hemodialysis, an average of 3 hemodialysis treatments per week prior to screening.
    3. Participant has demonstrated adequate hemodialysis measurements (at least 2 Kt/V measurements ≥ 1.2 or 2 urea reduction ratio measurements ≥ 65%) within the 3 months prior to screening.
  • Healthy participant should have a supine SBP ≥ 90 and ≤ 160 mm Hg, supine DBP ≥ 50 and ≤ 100 mm Hg, and heart rate ≥ 40 and ≤ 100 beats per minute.
  • Healthy participants should have normal renal function, as defined by having an eGFR ≥ 90 mL/min eGFR at screening (calculated using the CKD-EPI equation).

Exclusion criteria

Exclusion Criteria:

  • Participant with any significant medical condition, laboratory abnormality, or psychiatric illness.
  • Any surgical or medical condition(s) possibly affecting drug absorption, distribution, metabolism, or excretion (eg, bariatric procedure or cholecystectomy).
  • Individuals who are of , breastfeeding, or currently pregnant.
  • Other protocol defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Group A and C

    Drug: BMS-986278

  • Experimental
    Group B: Period 1

    Drug: BMS-986278

  • Experimental
    Group B: Period 2

    Drug: BMS-986278

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to Day 8

  2. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]

    Time frame: Up to Day 8

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]

    Time frame: Up to Day 8

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 28 days following discontinuation of dosing

  2. Number of participants with physical examination abnormalities

    Time frame: Up to Day 8

  3. Number of participants with vital sign abnormalities

    Time frame: Up to Day 8

  4. Number of participants with 12-lead electrocardiogram (ECG) abnormalities

    Time frame: Up to Day 8

  5. Number of participants with clinical laboratory abnormalities

    Time frame: Up to Day 8

  6. Time of maximum observed concentration (Tmax)

    Time frame: Up to Day 8

  7. Terminal elimination half-life (T-HALF)

    Time frame: Up to Day 8

  8. Apparent body clearance (CLT/F)

    Time frame: Up to Day 8

  9. Apparent volume of distribution of terminal phase (Vz/F)

    Time frame: Up to Day 8

  10. Concentration of BMS-986278 in dialysate

    Time frame: Up to Day 8

  11. Total amount recovered in dialysate (DR)

    Time frame: Up to Day 8

  12. Total percent of administered dose recovered in dialysate (%DR)

    Time frame: Up to Day 8

  13. Free fraction of unbound drug (Fu)

    Time frame: Up to Day 8

  14. Unbound Cmax (Cmax_u)

    Time frame: Up to Day 8

  15. Unbound AUC(0-T) (AUC(0-T) _u)

    Time frame: Up to Day 8

  16. Unbound AUC(INF) (AUC(INF)_u)

    Time frame: Up to Day 8

  17. Unbound CLT/F (CLT/F_u)

    Time frame: Up to Day 8

  18. Unbound Vz/F (Vz/F_u)

    Time frame: Up to Day 8

07

Study locations

4 sites
  • Local Institution - 0002
    Miami, Florida 33147-4040, United States
  • Local Institution - 0003
    Miami, Florida 33172, United States
  • Local Institution - 0004
    Orlando, Florida 32808-7820, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809-3017, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Sep 2025, 9 months.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 9 months is above that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Dec 9, 2024
StartActual
Dec 7, 2024
Primary completionActual
Sep 16, 2025
CompletionActual
Sep 19, 2025
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06723535
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Dec 7, 2024
Primary completion
Sep 16, 2025
Completion
Sep 19, 2025
Last update
Oct 14, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Admilparant

Start the discussion